Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase Over 1.5 Million Ordinary Shares

David M. Mott, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 1,583,214 ordinary shares on July 1, 2024.

Summary

• On July 1, 2024, David M. Mott, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 1,583,214 ordinary shares.
• The exercise price of these options is $0.16, converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00.
• The options are exercisable from July 1, 2025, and expire on July 1, 2034.
• Following this transaction, Mr. Mott directly owns 1,583,214 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of options by a director could be seen as a slightly positive sign, but it's a routine transaction.

Positives

• A director's acquisition of options may signal confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies across various industries.
• The size and nature of the transaction (options grant) are typical for director compensation packages.
• Comparing the option exercise price and vesting schedule to those of similar biotech companies would provide further context.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if interpreted as a sign of director confidence.

Key Dates